The said facility is operated by Jubilant Draximage Inc., a subsidiary of Jubilant Pharma (JPL), which is a wholly-owned subsidiary of Jubilant Pharmova. JPL is an ntegrated global pharmaceutical company engaged in manufacturing and supply of Radiopharmaceuticals with a network of 46 radio-pharmacies in the US; allergy immunotherapy, contract manufacturing of sterile injectables and non-sterile products and solid dosage formulations through five manufacturing facilities that cater to all the regulated market including USA, Europe and other geographies.

"The USFDA has issued 5 observations pursuant to the completion of audit. The company will submit an action plan on the observations," Jubilant Pharmova said in a statement.

Jubilant Pharmova is engaged in radiopharma, allergy immunotherapy, CDMO of sterile injectable, generics, contract research development and manufacturing (CRDMO) and proprietary novel drugs businesses.

The pharmaco has reported a net profit of Rs 66 crore in Q3 FY24 as against a net loss of Rs 16 crore in Q3 FY23. Total income increased by 10% YoY to Rs 1,713 crore during the period under review.

The scrip rose 0.25% to currently trade at Rs 684.25 on the BSE.